Alport Syndrome

4
Pipeline Programs
5
Companies
7
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
3
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

RNA Therapeutic
1100%
+ 6 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Sanofi
SanofiPARIS, France
2 programs
1
1
lademirsenPhase 2RNA Therapeutic1 trial
RG012Phase 11 trial
Active Trials
NCT03373786Completed4Est. May 2019
NCT02855268Terminated43Est. Sep 2022
Bayer
BayerLEVERKUSEN, Germany
1 program
1
BAY 3401016Phase 21 trial
Active Trials
NCT07211685Not Yet Recruiting60Est. Jul 2028
EP
Eloxx PharmaceuticalsIsrael - Nes Tziona
1 program
1
ELX-02Phase 21 trial
Active Trials
NCT05448755CompletedEst. Sep 2023
Novartis
NovartisBASEL, Switzerland
2 programs
Human Urine Sample Collection for Alport Nephropathy Biomarker StudiesN/A1 trial
Urinary Biomarkers of the Progression of Alport Kidney DiseaseN/A1 trial
Active Trials
NCT01602835Terminated80Est. May 2013
NCT01705132Completed80Est. Jul 2013
Pulse Biosciences
Pulse BiosciencesCA - Hayward
1 program
Longitudinal data collectionN/A1 trial
Active Trials
NCT06526741RecruitingEst. Aug 2048

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
BayerBAY 3401016
Eloxx PharmaceuticalsELX-02
Sanofilademirsen
SanofiRG012
Pulse BiosciencesLongitudinal data collection
NovartisHuman Urine Sample Collection for Alport Nephropathy Biomarker Studies
NovartisUrinary Biomarkers of the Progression of Alport Kidney Disease

Clinical Trials (7)

Total enrollment: 267 patients across 7 trials

NCT07211685BayerBAY 3401016

BAY3401016; Biomarker Study Alport

Start: Dec 2025Est. completion: Jul 202860 patients
Phase 2Not Yet Recruiting
NCT05448755Eloxx PharmaceuticalsELX-02

A Study of ELX-02 in Patients With Alport Syndrome

Start: Nov 2022Est. completion: Sep 2023
Phase 2Completed
NCT02855268Sanofilademirsen

Study of Lademirsen (SAR339375) in Patients With Alport Syndrome

Start: Nov 2019Est. completion: Sep 202243 patients
Phase 2Terminated
NCT03373786SanofiRG012

A Study of RG-012 in Subjects With Alport Syndrome

Start: Dec 2017Est. completion: May 20194 patients
Phase 1Completed
NCT06526741Pulse BiosciencesLongitudinal data collection

ASF Alport Patient Registry

Start: Aug 2023Est. completion: Aug 2048
N/ARecruiting
NCT01602835NovartisHuman Urine Sample Collection for Alport Nephropathy Biomarker Studies

Human Urine Sample Collection for Alport Nephropathy Biomarker Studies

Start: Sep 2012Est. completion: May 201380 patients
N/ATerminated
NCT01705132NovartisUrinary Biomarkers of the Progression of Alport Kidney Disease

Urinary Biomarkers of the Progression of Alport Kidney Disease

Start: Jun 2012Est. completion: Jul 201380 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 267 patients
5 companies competing in this space